Article Text

Download PDFPDF

LSO-065 Belimumab in combination with antimalarial agents prevent renal flares in patients with systemic lupus erythematosus and moderate-to-high extra-renal activity: results from four randomised clinical trials
  1. Alvaro Gomez1,
  2. Sandra Jägerback2,
  3. Christopher Sjöwall3 and
  4. Ioannis Parodis1,4
  1. 1Medicine Solna, Division of Rheumatology, Karolinska Institutet, Sweden
  2. 2Division of Rheumatology, Danderyd University Hospital, Sweden
  3. 3Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Sweden
  4. 4Rheumatology, Faculty of Medicine and Health, Örebro University, Sweden


Background We aimed to determine the effect of antimalarial agents (AMA) and different doses and pharmaceutical forms of belimumab on preventing renal flares in patients with systemic lupus erythematosus (SLE) treated for active extra-renal disease.

Methods We pooled data from the BLISS-52, BLISS-76, BLISS-SC and BLISS-Northeast Asia (NEA) randomised clinical trials of belimumab (N=3225), that included seropositive, active SLE patients with no active severe lupus nephritis (LN). Participants were allocated to receive intravenous (IV) belimumab 1 mg/kg (N=559), IV belimumab 10 mg/kg (N=1033), subcutaneous (SC) belimumab 200 mg (N=556) or placebo (N=1077) in addition to standard therapy. The outcome of the present post-hoc analysis was development of renal flares, defined according to the analysis plan within the BLISS programme. The hazard of renal flare was assessed with Cox proportional hazards regression models, adjusted for age, sex, ethnicity, previous renal involvement, baseline proteinuria and glomerular filtration rate, and use of glucocorticoids and immunosuppressants.

Results Demographic and clinical characteristics are shown in table 1. In total, 192 patients developed a renal flare after a median of 197 days. Compared with placebo, the risk of renal flares was lower among patients receiving IV belimumab 10 mg/kg (HR: 0.63; 95% CI: 0.45–0.87; p=0.005) and IV belimumab 1 mg/kg (HR: 0.40; 95% CI: 0.23–0.73; p=0.002) but not those receiving SC belimumab 200 mg. AMA use yielded a lower hazard of renal flares (HR: 0.65; 95% CI: 0.49–0.88; p=0.005). The protection conferred was enhanced when belimumab and AMA were co-administered, and the lowest flare rate was observed for the combination IV belimumab 1 mg/kg and AMA (18.5 cases per 1000 person-years).

Conclusions Belimumab in combination with AMA prevent against renal flares in patients treated for extra-renal SLE. The prominent effect of low-dose belimumab warrants investigation of the efficacy of intermediate doses.

Abstract LSO-065 Table 1

BLM: belimumab; UPCR: urine protein/creatinine ratio

  • Renal flares
  • Belimumab
  • Antimalarial agents

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.